Dyne therapeutics logo png
WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). WebDec 15, 2024 · The Trade: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes acquired a total of 934,581 shares at an average price of $10.70. To acquire these shares, it cost around $10 million. What ...
Dyne therapeutics logo png
Did you know?
WebMar 23, 2024 · DYNE-251 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of DMD in people who are amenable to exon 51 skipping. In addition to DYNE-251, Dyne is building a global DMD franchise with preclinical programs for patients with mutations amenable to skipping other exons, including 53, 45 and 44. WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Dyne Therapeutics Inc 50-day moving average is $12.61.
WebSep 17, 2024 · Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, raised $233 million by offering 12.3 million shares at $19, above the range of $16 to $18. WebJan 20, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular ...
WebDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary ... WebFind company research, competitor information, contact details & financial data for Dyne Therapeutics, Inc. of Waltham, MA. Get the latest business insights from Dun & …
WebCompany profile page for Dyne Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information
WebDyne Therapeutics. 239 likes · 14 talking about this. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing … how to get update hype gift in psxWebMar 24, 2024 · Dyne Therapeutics Inc Registered Shs's market capitalization is $642.40 M by 56.34 M shares outstanding. Dyne Therapeutics Stock Snapshot. ... Logos Global Management LP: 4.12: johnson and johnson formsWebDyne Therapeutics is a biotechnology company which offers targeted therapies for patients with cardiac diseases, and serious and smooth muscle diseases. The Company … how to get updated version of krnlWebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … johnson and johnson for pink eyeWebMay 14, 2024 · In January 2024, Dyne reported data showing that two doses (2 x 10 mg/kg) of its lead DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented ... how to get update hype gift psxWebJan 20, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy … how to get updated google earth imagesWebFeb 9, 2024 · Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne … how to get updates for excel